Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis
Status:
Completed
Trial end date:
2001-12-01
Target enrollment:
Participant gender:
Summary
- The primary objective of this study is to compare disease activity, as measured by PASI
score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by
intravenous infusion every 2 weeks for a total of 8 infusions.